ERBB2 and neoplasm: Further, there was no detailed treatment data available, particularly the registry lacked information on the type of surgery women had (mastectomy or lumpectomy), targeted treatment for HER2 + BCs which has likely affected survival of women with this tumour subtype in the last decades, nor data on BC recurrence.